STAAR Surgical director granted 11,145 stock options

STAAR Surgical director Christopher Min Fang Wang received a grant of stock options, acquiring rights to 11,145 shares of common stock.

Rhea-AI Filing Summary

STAAR Surgical director Christopher Min Fang Wang received a grant of stock options, acquiring rights to 11,145 shares of common stock. The options have an exercise price of $29.12 per share and were granted as compensation, not through open-market buying or selling.

These options vest in full on the earlier of June 18, 2027 or the company’s 2026 annual meeting of shareholders, and expire on June 18, 2036. After this grant, Wang holds 11,145 options directly under this award.

Insights

Equity compensation analyst

Director received a routine stock option grant tied to future service.

The filing shows Christopher Min Fang Wang, a director of STAAR Surgical, receiving 11,145 stock options at an exercise price of $29.12 per share. This is coded as an acquisition via grant, indicating standard equity compensation rather than a market trade.

The options vest in full on the earlier of the company’s 2026 annual meeting of shareholders or June 18, 2027, and expire on June 18, 2036. This structure encourages continued board service and long-term alignment with shareholders, but the impact on existing holders is modest given the relatively small grant size.

Insider Trade Summary

Grant/Award: 11,145 shares

Grant/Award 1 txn

Insider Wang Christopher Min Fang

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock Option	11,145	$0.00	$0.00

Holdings After Transaction: Common Stock Option — 11,145 contracts (Direct)

Footnotes (1)

1. F1. Award of stock options granted to the Reporting Person on June 18, 2026. These stock options will vest in full on the earlier of June 18, 2027 or the Issuer's 2026 annual meeting of shareholders.

Key Figures

Options granted: 11,145 options Exercise price: $29.12 per share Underlying shares: 11,145 shares +2 more

5 metrics

Options granted 11,145 options Grant of common stock options to director on June 18, 2026

Exercise price $29.12 per share Exercise price of granted stock options

Underlying shares 11,145 shares Common shares underlying the option grant

Expiration date June 18, 2036 Option grant expiration date

Post-grant options held 11,145 options Total options following this reported transaction

Key Terms

stock options, exercise price, vest in full, expiration date, +1 more

5 terms

stock options financial

"Award of stock options granted to the Reporting Person on June 18, 2026."

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"conversion_or_exercise_price": "29.1200""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"These stock options will vest in full on the earlier of June 18, 2027"

expiration date financial

"expiration_date": "2036-06-18T00:00:00.000Z""

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did STAAR Surgical (STAA) director Christopher Wang report in this Form 4?

Christopher Min Fang Wang reported receiving a grant of 11,145 stock options in STAAR Surgical. These options give him the right to buy common shares at a set price, representing equity compensation rather than an open-market stock purchase or sale.

How many STAAR Surgical stock options were granted to Christopher Wang and at what price?

Christopher Wang was granted 11,145 STAAR Surgical stock options with an exercise price of $29.12 per share. This means he can later buy up to 11,145 shares at $29.12, regardless of the future market price, subject to vesting conditions.

When do Christopher Wang’s STAAR Surgical stock options vest and expire?

The options vest in full on the earlier of June 18, 2027 or STAAR Surgical’s 2026 annual meeting of shareholders. They carry an expiration date of June 18, 2036, giving a long exercise window once vesting occurs, provided he meets the service conditions.

Is Christopher Wang’s STAAR Surgical Form 4 a stock purchase or sale?

The Form 4 reflects a grant of stock options, not a direct stock purchase or sale. It is coded as an acquisition via grant, meaning the company awarded options as compensation rather than Wang buying shares on the open market or selling existing holdings.

How many STAAR Surgical options does Christopher Wang hold after this grant?

Following this grant, Christopher Wang’s reported holdings from this award total 11,145 stock options. These options relate to 11,145 underlying shares of STAAR Surgical common stock, all held directly and subject to the specified vesting and expiration terms.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/23/2026 - 04:11 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wang Christopher Min Fang

(Last) (First) (Middle)

UNIT 3703, 37/F AIA TOWER

183 ELECTRIC ROAD, NORTH POINT

(Street)

HONG KONG K3 00000

(City) (State) (Zip)

HONG KONG

(Country)

2. Issuer Name and Ticker or Trading Symbol
STAAR SURGICAL CO [ STAA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Common Stock Option	$29.12	06/18/2026		A		11,145		(1)	06/18/2036	Common Stock, par value $0.01 per share	11,145	$0	11,145	D

Explanation of Responses:

1. Award of stock options granted to the Reporting Person on June 18, 2026. These stock options will vest in full on the earlier of June 18, 2027 or the Issuer's 2026 annual meeting of shareholders.

	/s/ Christopher Min Fang Wang	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)